Condition: Cataract · Presbyopia · Posterior Capsule Opacification · Sponsor: Bausch & Lomb Incorporated
The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.
This description comes directly from the study's public registry record.
Jennifer Laskowski · 8183699137 · jennifer.laskowski@bausch.com
Always discuss trial participation with your own doctor first.
| Trinity Research Group, LLC | Dothan, Alabama, United States | Recruiting |
| Feinerman Vision Center | Newport Beach, California, United States | Recruiting |
| Argus Research Center | Cape Coral, Florida, United States | Recruiting |
| Stephenson Eye Associates | Venice, Florida, United States | Recruiting |
| Virdi Eye Clinic and Laser Vision Center | Rock Island, Illinois, United States | Recruiting |
| Price Vision Group | Indianapolis, Indiana, United States | Recruiting |
| Grene Vision Group | Wichita, Kansas, United States | Recruiting |
| Oakland Eye | Birmingham, Michigan, United States | Recruiting |
| Vance Thompson Vision - Omaha | Omaha, Nebraska, United States | Recruiting |
| Eye Associates of New Jersey | Dover, New Jersey, United States | Recruiting |
| Northern New Jersey Eye Institute | South Orange, New Jersey, United States | Recruiting |
| Ophthalmic Partners, PC | Bala-Cynwyd, Pennsylvania, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06060041